Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study evaluating SEL-212 for chronic refractory gout
Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of enrolment for DISSOLVE I, the first of two clinical studies of the phase 3 DISSOLVE development programme of SEL-212 for chronic refractory gout. SEL-212 is a combination of Selecta’s ImmTOR™ immune tolerance platform and a therapeutic uricase enzyme (pegadricase). Guido Oelkers, President and Chief Executive Officer of Sobi, said “We are pleased that the DISSOLVE programme is progressing and we believe that the less burdensome treatment regimen of the